|
|
Anaphylaxis In Schools and Other Child Care Settings Introduction Anaphylaxis refers to a collection of symptoms (Appendix 1) affecting multiple systems in the body. The most dangerous are breathing difficulties, and a drop in blood pressure or shock which are potentially fatal. Common examples of potentially life threatening allergies are to foods and insects; life threatening allergic reactions may also occur to medications, exercise and latex rubber. The estimated risk of anaphylaxis in the general population is 1% to 2% for insect stings and foods, with a lower reported prevalence for drugs and latex (1). Approximately 50 anaphylactic insect sting deaths and 100 food related deaths are recognized each year in the USA (2,3) The most important aspect of the management of patients with life threatening allergies is avoidance. In the event of contact with the offending allergen, epinephrine (Adrenaline) by subcutaneous or intramuscular injection is the treatment of choice for anaphylaxis (1). Other medications such as antihistamines, inhaled asthma medications or steroids that subsequently may be given by physicians in treating anaphylaxis must not be regarded as first line medications. It is imperative that epinephrine be recognized as the drug of choice and all efforts be directed toward its immediate use (4,5). Data clearly shows that fatalities more often occur away from home and are associated with either not using or a delay in the use of epinephrine treatment (3). Anaphylaxis is a rare but preventable and treatable event. The Canadian Society for Allergy and Clinical Immunology together with provincial affiliates and allergy organizations have drafted this consensus statement to help simplify the management of anaphylaxis for the public. This is a working document that may be modified as future research dictates. Identifying the Problem Schools should develop a system of identifying children with life threatening allergies in order to prevent anaphylactic reactions. Staff members involved with the child's care must be instructed as to the potentially severe nature and proper treatment of the allergic problem. Review of this information should occur prior to the new school year or special activities (e.g. school trips). Any questions and possible treatment changes should then be addressed. All teachers must be aware of those students who may require epinephrine treatment. Aids could include identification sheets with the child's name, photograph, specific allergy (e.g. peanut, bee sting, etc.), warning signs of reaction and emergency treatment. This information should be readily available and reviewed by all care givers. Every child should have their own epinephrine auto-injector device labeled by name and expiry date. In addition each child should be wearing a Medic-Alert bracelet or necklace (badges in the nursery setting), clearly identifying their allergy. Avoidance Strategies Food Avoidance It is impractical to achieve complete avoidance of all allergenic foods as there can be hidden or accidentally introduced sources. However it is definitely possible to reduce children's exposure to allergenic foods within the school setting. We therefore feel that education and supervision are also paramount in dealing with issues regarding food allergies. Guidelines for children should include:
It should be stressed that minute amounts of certain foods like peanut when ingested can be life threatening (7). Several children have had skin rashes and stomach upsets just from simply contacting residual peanut butter on tables wiped clean of visible material (7). The potential risk of life threatening allergic reactions to airborne food particles such as peanut or shellfish is negligible. Presently we would not recommend a ban based on the risk of reactions from the inhalation route of exposure. The contents of foods served in school cafeterias and brought in for special events should be clearly identified. Terms that are not readily helpful such as casein, livetin or hydrolyzed vegetable protein, indicating the presence of milk, egg or peanut respectively need to be taught to personnel handling such foods. Information about these terms is available from national or provincial Allergy Information Associations. (See Appendix 3, Resource Listing). Food personnel should also be instructed about measures necessary to prevent cross contamination during the handling, preparation and serving of food. Peanut Avoidance Exposure to peanut is extensive in North America. Statistics for 1991 estimate that almost 5 billion pounds were consumed in the U.S.A. This is equivalent to 7 lb. per year for each American citizen (9). Canadian estimates are presumed to be comparable. Reactions to peanuts are often more severe than to other foods such as milk and egg. Peanut is ubiquitous in the food supply and in one study 50% of peanut allergic children had accidental peanut ingestion within one year of follow-up (10). In view of the nature of peanut allergies we therefore recommend these strong initiatives to control peanut exposure in the schools be instituted.
Insect Avoidance
Other Allergies Treatment Strategies EPINEPHRINE is the only drug which should be used in the emergency management of a child having a potentially life threatening allergic reaction. Epinephrine injection is available in a number of self administration delivery devices (appendix 2). We recommend the epinephrine auto-injector device because of its simplicity of use Epinephrine must be kept in locations which are easily accessible and not in locked cupboards or drawers. These locations should be known to all staff members. Children old enough to understand its proper use, should carry their own epinephrine. For younger children the epinephrine device should be kept in the classroom. Backup epinephrine auto-injectors should be available in other school areas such as gyms, assembly rooms, cafeterias, school yards, school buses, etc. All students regardless of whether or not they are capable of epinephrine self administration will still require the help of others because the severity of the reaction may hamper their attempts to inject themselves. Adult supervision is mandatory. All individuals entrusted with the care of children need to have familiarity with basic first aid and resuscitative techniques. This should include additional formal training on how to use epinephrine auto-injector devices. Policies for treating anaphylaxis should be implemented. Training programs may be through public health departments or physician's groups, to ensure that all individuals in schools and other areas of child care (school bus drivers, coaches, camp counselors, lifeguards, ambulance drivers, etc.) are certified in these techniques. Educational material is available from The Anaphylaxis Project of The Allergy Asthma Information Association. (See Appendix 3, Resource Listing). In this package there are two important forms that we would encourage to be completed. One is a consent form to be signed by the parents that allows the school to administer epinephrine. The second document is the Emergency Allergy Alert (protocol) Form. (See Action Plan, General Recommendations). The Food Allergy Network in the United States has also just completed an education packet and video on care of children with food allergies and anaphylaxis for schools. (See Appendix 3, Resource Listing). A potential barrier to the use of epinephrine is the fear of litigation. Common law protects the care givers in life threatening situations when they provide assistance in a reasonable and acceptable manner. The administration of epinephrine as outlined in this document is now regarded as acceptable treatment for anaphylaxis. Parents should be advised therefore to never sign a waiver absolving the school of responsibility if epinephrine was not injected. A position statement regarding the management of anaphylaxis has been drafted by the Allergy section of the Canadian Pediatric Society and serves as another source of information (11). Use of Epinephrine It is therefore recommended that epinephrine be given at the start of any reaction occurring in conjunction with a known or suspected allergy contact. In situations where there has been a history of a severe cardiovascular collapse to an allergen the physician may advocate that epinephrine be administered immediately after an insect sting or ingestion of the offending food and before any reaction has begun. ALL individuals receiving emergency epinephrine must immediately be transported to hospital. Epinephrine in the majority of cases will be effective after one injection. However, further treatments may be required and therefore observation in a hospital setting is necessary. Additional epinephrine must be available during transport and may be administered every 15 to 20 minutes (7). This should only be given in situations where the allergic response is not under adequate control: i.e. the patient's breathing becomes more labored or the patient has a decreasing level of consciousness. The need for multiple injections indicates the need for other emergency drugs. Therefore it is important when planning trips or camping outdoors that a hospital be within an hour travel time or there is easy access to police, fire or ambulance emergency services. Despite the initial adequate therapy of an actual life threatening episode of anaphylaxis repeat attacks have occurred up to 8 hours later without additional exposure to the offending allergen (13). Observation for 4 hours in an emergency facility is strongly recommended for other individuals with milder reactions. References
Appendix 1 COMMON SYMPTOMS AND SIGNS OF ALLERGIC REACTIONS
Appendix 2 EpiPen is available in two forms EpiPen Jr. and EpiPen. The EpiPen Jr., contains 2.0 ml of epinephrine 1:2000 dilution. One injection delivers 0.3 ml of fluid which contains 0.15 mg of epinephrine. This is used for those weighing 15 kg (33 lb.) or less. The EpiPen contains 2.0 ml of epinephrine 1:1000 dilution. One injection delivers 0.3 ml of fluid which contains 0.3 mg. of epinephrine. This is used for those weighing greater than 15 kg (33 lb.). A brochure outlining most of the aspects of handling and administering the Epinephrine auto-injector is entitled "For all allergic emergencies" and is available from Allerex Lab Ltd; 580 Terry Fox Drive, Suite 408, Kanata, Ontario K2L 4B9; Telephone No. (613) 592-8200. All those responsible for using EpiPens should be familiar with these instructions. A training EpiPen device is available from the same company. this can provide individuals with an appreciation of how much pressure is needed to activate the device until a "click" is heard. Management of Children with Life Threatening Allergies GENERAL RECOMMENDATIONS
Management of Specific Allergens
In the case of peanut allergy;
The child should be under close and constant supervision for 4 hours after the suspected / actual sting or ingestion. Administer the epinephrine auto-injector as soon as the child develops any one of the following symptoms and take him or her immediately to hospital. If no serious reaction occurs within 4 hours it is unlikely to occur.
Additional epinephrine must be available during transport and may be administe red every 15 to 20 minutes (7). This should only be given in situations where the allergic response is not under adequate control: i.e. the patient's breathing becomes more labored or the patient has a decreasing level of consciousness. The need for multiple injections indicates the need for other emergency drugs, therefore it is important when planning trips or camping outdoors that a hospital be within an hour travel time or there is easy access to police, fire or ambulance emergency services. NOTE:
Other Life Threatening Allergies The approach to these children is similar to that outlined for peanut and stinging insect allergy. Care of these children should be individualized based on discussions between the parent, the allergy specialist and the school. Appendix 3
Principle Authors MILTON GOLD MD., FRCP(C), Assistant Professor of Pediatrics, University of Toronto; Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario. GORDON SUSSMAN MD., FRCP(C), FACP, President, Canadian Society of Allergy & Clinical Immunology; Assistant Professor, University of Toronto; Head, Section of Allergy, Division of Immunology, The Wellesley Hospital, Toronto, Ontario. MICHAEL LOUBSER MB.BCh, FCP (SA), Assistant Professor of Pediatrics, University of Toronto; Division of Immunology and Allergy, The Hospital for Sick Children, Toronto, Ontario. KAREN BINKLEY MD., FRCP(C), Instructor, University of Toronto; Division of Allergy, St. Michael's Hospital, Toronto, Ontario. Contributing Authors MEGAN BOYES Regional Co-ordinator, Allergy Asthma Information Association. ZAVE CHAD MD., FRCP(C), Clinical Associate Professor of Pediatrics, University of Montreal, Montreal, Quebec. DAVID CROSS MD., CM., FRCP(C), pc. Specialist in Allergy and Clinical Immunology, Calgary, Alberta. SUSAN DAGLISH Executive Director, Allergy Asthma Information Association. JERRY DOLOVICH MD., FRCP(C), Professor of Pediatrics, McMaster University, Hamilton, Ontario. MICHEL DROUIN MD., FRCP(C), Head, Allergy Service, Ottawa General Hospital; Clinical Assistant Professor of Medicine, University of Ottawa, Ottawa,Ontario. ALEXANDER FERGUSON MD., ChB., FRCP(C), Professor of Pediatrics, University of British Columbia; Division of Allergy, BC Children's Hospital, Vancouver, BC. BETH GOLDSTEIN Advisory Board Member, Ontario Anaphylaxis Project, Allergy Asthma Information Association. MARY HOCKIN Chairperson, London, Ontario Chapter, Allergy Asthma Information Association. DAVID HUMMEL MD., FRCP(C), Assistant Professor of Pediatrics, University of Toronto; Division of Immunology and Allergy, Hospital for Sick Children, Toronto, Ontario. ARTHUR KAMINKER MD., FRCP(C), President, Ontario Allergy Association; Department of Medicine, Toronto East General Hospital, Toronto, Ontario. ERIC LEITH MD., FRCP(C), Chief, Department of Medicine, Oakville-Trafalgar Memorial Hospital, Oakville; Active Staff, Department of Medicine, Women's College Hospital; Lecturer, Department of Medicine, University of Toronto, Toronto, Ontario. DEENA MANDELL Advisory Board Member, Ontario Anaphylaxis Project, Allergy Asthma Information Association. KEITH PAYTON MD., FRCP(C), Chief, Allergy & Asthma Clinic, St. Joseph's Health Centre; Professor of Medicine, University of Western Ontario, London, Ontario. HUGH A. SAMPSON MD., Professor of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. LAWRENCE B. SCHWARTZ MD., PhD., Professor of Medicine, Head of Allergy and Clinical Immunology, Medical College of Virginia, Richmond, Virginia. DONALD STARK MD., FRCP(C), Clinical Associate Professor, University of British Columbia, Vancouver, BC. PETER VADAS MD., PhD., FRCP(C), FACP, Director, Regional Anaphylaxis Clinic, Division of Immunology, Department of Medicine, The Wellesley Hospital, Toronto, Ontario. WADE WATSON MD., FRCP(C), Associate Professor, Section of Allergy & Clinical Immunology, Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Manitoba. MARTHA WEBER Chairperson, Ontario Anaphylaxis Project, Allergy Asthma Information Association. JOHN W. YUNGINGER MD., Professor of Pediatrics, Mayo Medical School. BARRY ZIMMERMAN MD., FRCP(C), Member, The Asthma Centre, Toronto Hospital/Western Division, Toronto, Ontario. © First Printing: August 1995 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||